Cargando...
Targeting molecular resistance in castration-resistant prostate cancer
Multiple mechanisms of resistance contribute to the inevitable progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved therapies for CRPC include systemic chemotherapy (docetaxel and cabazitaxel) and agents targeting the resistance pathways...
Gardado en:
| Publicado en: | BMC Med |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4556222/ https://ncbi.nlm.nih.gov/pubmed/26329698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0457-6 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|